New Antibody Cocktail Offers Broad Protection Against All Ebola Virus Species
A two-antibody treatment shows pan-ebolavirus protection in animal models, raising hopes for tackling deadly BDBV outbreaks.
Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
675 articles
A two-antibody treatment shows pan-ebolavirus protection in animal models, raising hopes for tackling deadly BDBV outbreaks.
Sunlight exposure in ICUs and circadian light tracking may accelerate recovery and reduce mortality risk for critically ill patients.
Hospitals are testing sunroof ICUs to restore natural light. Here's why infrared light matters for recovery and longevity.
A Phase 2 trial tests whether selatogrel, a subcutaneous P2Y12 inhibitor, can rapidly block platelet aggregation in stable coronary artery disease patients.
The PARTNER 3 trial's 7-year data show TAVR and surgical valves fail at nearly identical rates in low-risk patients.
The new ACC/AHA guideline introduces childhood screening, Lp(a) testing, and LDL-C treatment targets that reshape primary prevention care.
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
A newly discovered Ral GTPase pathway degrades LDLR receptors in response to dietary cholesterol — and blocking it may lower LDL.
An AI-powered ECG algorithm flagged hidden structural heart disease, setting a patient on the path to a successful heart transplant.
Scientists reveal CFTR protein prevents cardiomyocyte senescence by reducing mitochondrial oxidative stress via a newly discovered deubiquitination pathway.
A pilot RCT tests whether a values-based psychological intervention can improve medication adherence in heart failure patients undergoing cardiac rehab.
Leading cardiologists outline critical unanswered questions about aldosteronism and its underappreciated role in cardiovascular disease.